The medication EVG7 proves effective not only in eradicating the bacterium Clostridioides difficile but also in preserving the beneficial gut microbiota.
C. difficile infection represents a significant public health challenge, targeting the elderly and immunocompromised individuals particularly hard. This bacterium releases toxins, leading to severe diarrhea and inflammation. A major hurdle in treatment is the considerable risk of recurrence.
Conventional antibiotics, such as vancomycin, successfully kill the pathogen but simultaneously decimate the protective bacteria residing in the gut. This leaves C. difficile spores capable of surviving and reactivating, often weeks later.
The findings of this study have been published in Nature Communications.
EVG7, engineered in the laboratory of Professor Nathaniel Martin at Leiden University, is a more potent iteration of the antibiotic vancomycin. Due to its enhanced efficacy, scientists were able to administer it in an exceptionally small dosage. The outcomes surpassed expectations:
Complete Infection Clearance. A low dose of EVG7 successfully purged C. difficile from the subjects’ systems (mice).
Relapse Prevention. Unlike treatments using standard protocols, the infection did not return.
Microbiome Protection. Analysis revealed that the drug acts selectively against the pathogen, leaving beneficial bacteria untouched, specifically those belonging to the Lachnospiraceae family. The researchers emphasize that these particular bacteria actually confer protection against C. difficile.
By safeguarding these microbes, any chance for the infection spores to reignite is eliminated.
The application of minute doses sometimes raises concerns regarding the potential for bacteria to develop resistance. However, the research team asserts that EVG7 is so powerful that it entirely eliminates the pathogen, preventing it from entering a “stressed” state that facilitates mutation and strengthening.
The ensuing step involves toxicology studies, which are prerequisites for commencing human clinical trials. Should these prove successful, testing on human volunteers could commence within a few years.
The primary barrier identified by the scientists is securing funding. Lead author Elma Mons notes, “Pharmaceutical companies realize far less profit from antibiotics compared to, say, cancer medications, leading to limited investor interest.” Nevertheless, the researchers remain convinced of the development’s potential, given that the expense associated with readmitting patients suffering from recurrent infections also imposes a heavy financial burden on the healthcare system.
About the Author
